4-(2-氨基苯氧基)苯甲酸甲酯 | 113187-84-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2-氨基苯氧基)苯甲酸甲酯
• 英文名称: 4-(2-amino-phenoxy)-benzoic acid methyl ester
• 英文别名: 4-(2-Amino-phenoxy)-benzoesaeure-methylester；2'-Amino-diphenylaether-carbonsaeure-(4)-methylester；Methyl 4-(2-aminophenoxy)benzoate
• CAS: 113187-84-1
• 化学式: C₁₄H₁₃NO₃
• 分子量: 243.262
• InChiKey: WUELUEATXCULFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2922509090

反应信息

• 作为反应物：
  描述：

  4-(2-氨基苯氧基)苯甲酸甲酯 生成 4-(2-amino-phenoxy)-benzoic acid
  参考文献：
  名称：

  Mayer; Krieger, Chemische Berichte, 1922, vol. 55, p. 1664

  摘要：

  DOI：
• 作为产物：
  描述：

  1-溴-2-硝基苯 在 ammonium sulfide 作用下， 生成 4-(2-氨基苯氧基)苯甲酸甲酯
  参考文献：
  名称：

  Mayer; Krieger, Chemische Berichte, 1922, vol. 55, p. 1664

  摘要：

  DOI：

文献信息

• Aryl carbonyl derivatives as therapeutic agents
  申请人：——

  公开号：US20040122235A1

  公开（公告）日：2004-06-24

  This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

  本发明涉及芳基羰基衍生物，其是葡萄糖激酶的激活剂，可用于管理、治疗、控制或辅助治疗增加葡萄糖激酶活性有益的疾病。
• ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS
  申请人：Polisetti Dharma Rao

  公开号：US20110301158A1

  公开（公告）日：2011-12-08

  This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

  本发明涉及芳基羰基衍生物，它们是葡萄糖激酶的活化剂，可能有助于管理、治疗、控制或辅助治疗增加葡萄糖激酶活性有益的疾病。
• Ikawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1955, vol. 75, p. 457,459
  作者：Ikawa

  DOI：——

  日期：——
• High-throughput identification of antibacterials against methicillin-resistant Staphylococcus aureus (MRSA) and the transglycosylase
  作者：Ting-Jen Rachel Cheng、Ying-Ta Wu、Shih-Ting Yang、Kien-Hock Lo、Shao-Kang Chen、Yin-Hsuan Chen、Wen-I Huang、Chih-Hung Yuan、Chih-Wei Guo、Lin-Ya Huang、Kuo-Ting Chen、Hao-Wei Shih、Yih-Shyun E. Cheng、Wei-Chieh Cheng、Chi-Huey Wong

  DOI：10.1016/j.bmc.2010.10.036

  日期：2010.12

  To identify new transglycosylase inhibitors with potent anti-methicillin-resistant Staphylococcus aureus (MRSA) activities, a high-throughput screening against Staphylococcus aureus was conducted to look for antibacterial cores in our 2 M compound library that consists of natural products, proprietary collection, and synthetic molecules. About 3600 hits were identified from the primary screening and the subsequent confirmation resulted in a total of 252 compounds in 84 clusters which showed anti-MRSA activities with MIC values as low as 0.1 mu g/ml. Subsequent screening targeting bacterial transglycosylase identified a salicylanilide-based core that inhibited the lipid II polymerization and the moenomycin-binding activities of transglycosylase. Among the collected analogues, potent inhibitors with the IC50 values below 10 mu M against transglycosylase were identified. The non-carbonhydrate scaffold reported in this study suggests a new direction for development of bacterial transglycosylase inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.
• USRE045670E1
  申请人：——

  公开号：——

  公开（公告）日：——